Immucell CORP (ICCC) 13F Holdings Overview (Q2 2026)

ICCC ranks #7395 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ICCC is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

31 institutions disclose a position in ICCC, but none treat it as a major bet — even Steadtrust LLC, its most concentrated holder, allocates just 0.2% of its own portfolio to it.

Morgan Stanley has added to its ICCC position for two straight quarters, increasing it by $1.6M to reach $2.4M today.

ICCC posted net income of $787.4K over the trailing twelve months, and currently trades at a P/E of 113.9.

• Profitable — net income of $787.4K over the trailing twelve months
• Revenue grew 8.5% year over year
• Net income declined year over year, from $1.8M to $787.4K
• Generated $2.5M in positive operating cash flow
• Current ratio of 4.26x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.57x equity — within a conventional range